Novo Nordisk ( NVO 0.15%) has found phenomenal success in treating patients with obesity and diabetes. *Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

The Bill and Melinda Gates Foundation is a charitable organization that has spent tens of billions of dollars fighting global ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

COPENHAGEN: Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday (Dec 20) after it announced disappointing ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company’s experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patien ...

The Novo Nordisk Foundation is supporting the initiative with up to DKK 1.05 billion (€134.1 million). Our daily lives are full of products and processes based on fossil materials or created using ...